Please select the eligibility criteria that correspond to the clinical trial below.
Title: Effects of a Supervised Progressive Resistance Training With Breast Cancer Patients During Adjuvant Radiotherapy - A Randomised Controlled Intervention Trial
Brief Summary: The purpose of this randomized intervention study is to investigate the effects and biological mechanisms of a supervised 12-week progressive resistance training on fatigue and immunological and inflammatory biomarkers in breast cancer patients during adjuvant radiotherapy. To determine the effect of the exercise itself beyond potential psychosocial effects due to attention by trainers or the group support, patients in the control group have a comparable training schedule (i.e. 60 min, twice a week, for 12 weeks) but with relaxation training (Jacobsen method).


Options:
A: Inclusion Criteria:

* men aged 50 years or older
* diagnosed with adenocarcinoma prostate cancer
* will initiate and receive continuous ADT (luteinizing hormone releasing hormone agonist (LHRH) or combination of LHRH and anti-androgen) for at least 12 months after recruitment
* Patients will also consent to participating in the study.

Exclusion Criteria:

* severe cardiac disease (New York Heart Association class III or greater)
* angina
* severe osteoporosis
* uncontrolled hypertension (blood pressure \> 160/95mm Hg)
* orthostatic blood pressure drop \> 20mm Hg
* moderate to severe aortic stenosis
* acute illness or fever
* uncontrolled atrial or ventricular dysrhythmias
* uncontrolled sinus tachycardia (\> 120 beats per minute)
* uncontrolled congestive heart failure third-degree atrio-ventricular heart block, active pericarditis or myocarditis, recent embolism, thrombophlebitis, deep vein thrombosis, resting ST displacement (\> 3mm), uncontrolled diabetes, uncontrolled pain, cognitive impairment, history of falls due to balance impairment or lost of consciousness, severe neuromusculoskeletal conditions that limit their ability to perform walking exercise (including ataxia, peripheral or sensory neuropathy, unstable bone lesion, severe arthritis, pathological lower limb fractures within 6 months, lower limb amputation).
B: Inclusion Criteria:

* histologically confirmed primary breast cancer, stage I-III, after lumpectomy or mastectomy, indication for adjuvant radiotherapy
* BMI: 18-40
* ability to understand and follow the study protocol

Exclusion Criteria:

* contraindication for exercise
* participation in the BEATE trial or another systematic resistance or relaxation training
C: Inclusion Criteria:

* men aged 50 or older
* diagnosed with adenocarcinoma prostate cancer
* will initiate and receive continuous ADT (LHRH or combination of LHRH and anti-androgen for at least 6 months

Exclusion Criteria:

* severe cardiac disease (New York Heart Association class III or greater)
* angina
* severe osteoporosis
* uncontrolled hypertension
* orthostastic blood pressure drop \> 20mm Hg
* moderate to severe aortic stenosis
* acute illness or fever
* uncontrolled atrial or ventricular dysrhythmias
* uncontrolled sinus tachycardia (\> 120 beats per minute)
* uncontrolled congestive heart failure
* third-degree atrio-ventricular heart block
* active pericarditis or myocarditis
* recent embolism, thrombophlebitis
* deep vein thrombosis, resting ST displacement
* uncontrolled diabetes
* uncontrolled pain
* cognitive impairment
* history of falls due to balance impairment or lost of consciousness
* severe neuromusculoskeletal conditions that limit their ability to perform walking exercise
D: Inclusion Criteria:

* Reside in Austin, Texas or Travis County
* African, Caucasian, or Hispanic heritage
* Fluent in reading and speaking English
* Mini Mental Exam scores of 23-30
* Pass executive function test
* Adequate hearing and vision to enable participation in classroom learning
* Free of Alzheimer's disease or other conditions (e.g., certain cancers) likely to result in mortality before study completion

Exclusion Criteria:

* Under 65
* Score less than 23 on MMSE
* Fail the executive function tests
* Severe sensory losses, hearing or vision, that would prohibit testing or participation
* self-report a diagnosis of Alzheimer's disease or other conditions (e.g., certain cancers) likely to result in mortality before study completion

Answer: B